Alector (ALEC) Competitors $5.10 -0.03 (-0.58%) (As of 12:35 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ALEC vs. RGNX, CCCC, NK, ITOS, INBX, SYRE, MIRM, RXRX, NRIX, and IRONShould you be buying Alector stock or one of its competitors? The main competitors of Alector include REGENXBIO (RGNX), C4 Therapeutics (CCCC), NantKwest (NK), iTeos Therapeutics (ITOS), Inhibrx (INBX), Spyre Therapeutics (SYRE), Mirum Pharmaceuticals (MIRM), Recursion Pharmaceuticals (RXRX), Nurix Therapeutics (NRIX), and Disc Medicine (IRON). These companies are all part of the "medical" sector. Alector vs. REGENXBIO C4 Therapeutics NantKwest iTeos Therapeutics Inhibrx Spyre Therapeutics Mirum Pharmaceuticals Recursion Pharmaceuticals Nurix Therapeutics Disc Medicine REGENXBIO (NASDAQ:RGNX) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership. Do institutionals & insiders hold more shares of RGNX or ALEC? 88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 13.1% of REGENXBIO shares are owned by insiders. Comparatively, 9.1% of Alector shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts rate RGNX or ALEC? REGENXBIO currently has a consensus price target of $37.00, suggesting a potential upside of 224.85%. Alector has a consensus price target of $17.75, suggesting a potential upside of 252.88%. Given Alector's stronger consensus rating and higher possible upside, analysts clearly believe Alector is more favorable than REGENXBIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score REGENXBIO 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91Alector 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in RGNX or ALEC? REGENXBIO received 280 more outperform votes than Alector when rated by MarketBeat users. Likewise, 65.75% of users gave REGENXBIO an outperform vote while only 61.54% of users gave Alector an outperform vote. CompanyUnderperformOutperformREGENXBIOOutperform Votes43265.75% Underperform Votes22534.25% AlectorOutperform Votes15261.54% Underperform Votes9538.46% Which has more risk & volatility, RGNX or ALEC? REGENXBIO has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Alector has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Is RGNX or ALEC more profitable? Alector has a net margin of -257.54% compared to REGENXBIO's net margin of -283.19%. REGENXBIO's return on equity of -70.65% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets REGENXBIO-283.19% -70.65% -41.68% Alector -257.54%-108.77%-27.03% Does the media refer more to RGNX or ALEC? In the previous week, REGENXBIO had 4 more articles in the media than Alector. MarketBeat recorded 20 mentions for REGENXBIO and 16 mentions for Alector. Alector's average media sentiment score of 0.85 beat REGENXBIO's score of 0.14 indicating that Alector is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 6 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alector 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, RGNX or ALEC? Alector has higher revenue and earnings than REGENXBIO. Alector is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioREGENXBIO$84.33M6.69-$263.49M-$5.03-2.26Alector$97.06M5.08-$130.39M-$1.70-2.96 SummaryREGENXBIO beats Alector on 10 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Claim your FREE book now before it's too late! Get Alector News Delivered to You Automatically Sign up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALEC vs. The Competition Export to ExcelMetricAlectorBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$492.59M$3.09B$5.18B$8.91BDividend YieldN/A1.76%4.98%4.03%P/E Ratio-2.9646.44135.1217.44Price / Sales5.08299.541,248.6491.11Price / CashN/A179.8138.8936.42Price / Book4.164.406.305.92Net Income-$130.39M-$42.42M$118.33M$224.86M7 Day Performance-10.82%-3.93%-1.54%-0.45%1 Month Performance2.65%3.75%2.98%4.16%1 Year Performance16.98%36.20%36.39%27.33% Alector Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALECAlector4.4145 of 5 stars$5.10-0.6%$17.75+248.0%+35.9%$499.44M$97.06M-3.00270Analyst RevisionRGNXREGENXBIO4.3878 of 5 stars$11.16-0.3%N/A-39.9%$552.92M$90.24M-2.22344Analyst RevisionHigh Trading VolumeCCCCC4 Therapeutics2.026 of 5 stars$6.06+0.3%N/A+207.2%$421.42M$20.76M-3.56150Short Interest ↓NKNantKwestN/A$5.57+5.1%N/A+40.4%$609.05M$40,000.00-7.85160High Trading VolumeITOSiTeos Therapeutics3.1407 of 5 stars$9.27+1.0%N/A-8.0%$338.56M$35M-3.0990Analyst ForecastShort Interest ↓News CoverageINBXInhibrx3.9789 of 5 stars$16.21-0.3%N/A-21.5%$234.66M$1.69M0.00166Short Interest ↑SYRESpyre Therapeutics2.4719 of 5 stars$39.58+5.0%N/AN/A$2.02B$890,000.00-2.56100Analyst ForecastAnalyst RevisionNews CoverageMIRMMirum Pharmaceuticals4.4495 of 5 stars$42.00+2.2%N/A+44.0%$2.00B$186.37M-18.34140Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageRXRXRecursion Pharmaceuticals2.122 of 5 stars$7.10+2.5%N/A+25.6%$2.00B$44.58M-4.64400Analyst RevisionNRIXNurix Therapeutics0.9893 of 5 stars$27.34+0.4%N/A+416.2%$1.94B$56.42M-9.40300IRONDisc Medicine3.0589 of 5 stars$65.00+2.6%N/A+27.2%$1.93BN/A-17.7178Earnings ReportAnalyst ForecastShort Interest ↑Analyst Revision Related Companies and Tools Related Companies REGENXBIO Alternatives C4 Therapeutics Alternatives NantKwest Alternatives iTeos Therapeutics Alternatives Inhibrx Alternatives Spyre Therapeutics Alternatives Mirum Pharmaceuticals Alternatives Recursion Pharmaceuticals Alternatives Nurix Therapeutics Alternatives Disc Medicine Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALEC) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersIs Your 401(k) Safe? The Real Risk No One Sees ComingEvery day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopp...Golden Crest | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alector With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
